Qben Infra - Portfolio reshaping continues
The reshaping continues......with a potential IPO of the land bank......and large cost-cutting measuresQ4 highlightsQben Infra reported Q4 sales of SE...
- Alligo
- Arctic Paper
- Ascelia Pharma
- B3 Consulting Group
- BTS Group
- Byggmästaren
- Careium
- Catella
- Cavotec
- Clavister
- Coor
- CTT Systems
- Eastnine
- Eltel
- Embellence Group
- Energy Save
- Eolus
- Ework Group
- Fastpartner
- Ferronordic
- Formpipe
- G5 Entertainment
- Generic
- Gentoo Media
- Impact Coatings
- Infrea
- Inission
- INVISIO
- Isofol Medical
- I-tech
- Lumi Gruppen
- Medicover
- Midsona
- Nexam Chemical
- Nilörn
- Nolato
- NYAB
- Ogunsen
- OrganoClick
- OssDsign
- Ovzon
- Petrolia Noco
- Prevas
- Proact
- Qben Infra
- SinterCast
- Skolon
- Stenhus Fastigheter
- StrongPoint
- Studsvik
- Svedbergs Group
- Tempest Security
- Viscaria
- Xplora Technologies
Press the button and be introduced to a new random company!
Social media
Follow us on Twitter
Latest Equity Research
Xplora Technologies - Record quarter driven by Senior
Q4 sales and EBITDA 7% and EBITDA 23% above driven by SeniorStrong growth in senior device revenue +35% y-o-yExpect cons to lift '26 EBITDA by 10-15%,...
Isofol Medical - From first lessons to second execution
Strong early efficacy signalSolid cost managementFair value range of SEK 0.1-10.5/shareStrong early efficacy signalIsofol today announced that all six...
B3 Consulting Group - Cost adjustments should lift margins in '26e
Minor negative estimate revisions due to lower headcountContinued negative net recruitment trend, but increasing marginsTrading at NTM EV/EBITA of 5.5...
Ework Group - Market conditions yet to improve
Market remains challenging; soft near-term outlookWe lower '26e-'27e adj. EBIT by 33%12x-10x 2026e EV/EBIT adj.Weak Q4, automotive remains the main cu...
Formpipe - Good margins, but ACV lags
Weak ACV, but good marginsWe lower our sales assumptions, but raise '26e-'27e EBIT margins1.7x EV/sales in '26e (excl. the DPS of SEK 14), 15x EV/EBIT...
Energy Save - Back to growth, but softer H1'26 expected
Q4: Back to growth and positive EBIT; sales +12% vs. ABGSCeSeasonally softer H1'26e, stronger H2'26e expectedWe cut '26e-'27e sales by 4-3% and total ...
Show more